EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam

Van Luan Pham iD, Cam Phuong Pham iD, Thi Thai Hoa Nguyen, Tuan Khoi Nguyen, Minh Hai Nguyen, Thi Anh Thu Hoang, Tuan Anh Le, Dinh Thy Hao Vuong iD, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Hung Kien Do iD und 8 weitere

Therapeutic Advances in Respiratory Disease · 2025

DOI: 10.1177/17534666251341747 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2025. Verfasst von Van Luan Pham und 19 weiteren Autor:innen. Beteiligte Einrichtung: Military Central Hospital 108, Hanoi, Vietnam. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Afatinib, Lung Neoplasms, Mutation. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Afatinib is indicated for patients with advanced-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, including uncommon mutations. However, the differences in survival benefits between patients with different types of EGFR mutations remain unclear.

Objectives

This study aimed to compare the effectiveness of afatinib treatment in patients harboring the EGFR-G719X mutation with that in patients carrying other uncommon EGFR mutations.

Design

This was a retrospective study.

Methods

Ninety-two patients with locally advanced and metastatic NSCLC, of whom 49 patients with EGFR-G719X mutations that were both single and compound, and 43 patients harbored other uncommon EGFR mutations, who were treated with afatinib as first-line treatment. The patients were followed up and evaluated every 3 months or when there were symptoms of progressive disease. The endpoints were the objective response rate (ORR), time-to-treatment failure (TTF), and overall survival (OS).

Results

The average ages of patients with the EGFR-G719X and uncommon EGFR mutations were 62.7 years and 63.1 years, respectively. There were no significant differences in sex or smoking history between the two groups. In total, 28.6% of patients with the G719X mutation and 23.3% of patients with other mutations had brain metastases. The ORR of patients with the G719X mutation was 79.6%, which was 10% higher than that of patients with other EGFR mutations. Patients harboring the EGFR-G719X mutation had median TTF and median OS periods of 19.3 months and 31.4 months, respectively, which were significantly higher than those of patients carrying other mutations at 11.2 months. Subgroup analysis showed that TTF and OS benefits were observed in female patients, patients without brain metastasis, and patients with good performance status who harbored the G719X mutation.

Conclusion

Patients with the EGFR-G719X mutation achieve significantly better TTF and OS benefits than those with other uncommon EGFR mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAfatinibLung NeoplasmsMutationProtein Kinase InhibitorsAntineoplastic AgentsHumansFemaleMaleMiddle AgedErbB ReceptorsRetrospective StudiesAgedVietnamNeoplasm StagingAdultTime FactorsTreatment Outcome

Stichwörter der Autor:innen

G719Xafatinib first linenon-small cell lung canceruncommon EGFR mutations

Substanzen

AfatinibErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Military Central Hospital 108, Hanoi, Vietnam.
  • College of Health Sciences, VinUniversity, Vietnam.
  • Hanoi Medical University, Hanoi, Vietnam.
  • Bach Mai Hospital, Giai Phong, Hanoi, Vietnam.
  • University of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam.
  • Vietnam National Cancer Hospital, Hanoi, Vietnam.

ORCID-Profile: Van Luan Pham, Cam Phuong Pham, Dinh Thy Hao Vuong, Hung Kien Do, Ha Thanh Vu, Van Thai Pham, Hoang Gia Nguyen, Cong Minh Truong

Zitieren

APA

Pham, V. L., Pham, C. P., Nguyen, T. T. H., Nguyen, T. K., Nguyen, M. H., Hoang, T. A. T., Le, T. A., Vuong, D. T. H., Nguyen, D. N. T., Dang, V. K., Nguyen, T. O., Do, H. K., Vu, H. T., Nguyen, T. T. H., Pham, V. T., Trinh, L. H., Nguyen, H. G., Truong, C. M., Pham, T. M. C., & Nguyen, T. B. P. (2025). Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666251341747

Vancouver

Pham VL, Pham CP, Nguyen TTH, Nguyen TK, Nguyen MH, Hoang TAT, et al. Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam. Therapeutic Advances in Respiratory Disease. 2025. doi:10.1177/17534666251341747

BibTeX
@article{Pham2025,
  author = {Pham, Van Luan and Pham, Cam Phuong and Nguyen, Thi Thai Hoa and Nguyen, Tuan Khoi and Nguyen, Minh Hai and Hoang, Thi Anh Thu and Le, Tuan Anh and Vuong, Dinh Thy Hao and Nguyen, Dac Nhan Tam and Dang, Van Khiem and Nguyen, Thi Oanh and Do, Hung Kien and Vu, Ha Thanh and Nguyen, Thi Thuy Hang and Pham, Van Thai and Trinh, Le Huy and Nguyen, Hoang Gia and Truong, Cong Minh and Pham, Tran Minh Chau and Nguyen, Thi Bich Phuong},
  title = {Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2025},
  doi = {10.1177/17534666251341747}
}
Kostenlos starten →